Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

In a survey of 2,000 single adults ages 18 to 91 conducted by Indiana University, among those taking GLP-1 drugs to lose ...

Researchers at St. Louis University followed 110 men with obesity, many with type 2 diabetes, who were being treated with GLP ...

NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new ...

Officials with the Food and Drug Administration have approved the continued sales of tobacco-flavored e-cigarettes and refill ...

Drug development is a decade-long, costly process replete with failures. If we don’t incentivize investments in research and ...

The following is a special feature from CivicScience CEO and Founder John Dick. Learn how you can turn insights like these ...

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

KANSAS CITY — The concept of food as medicine is catching on among consumers who are taking health and wellness into their ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an incr ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP-1 RAs.